Exposure–Response Modeling and Simulation of Progression‐Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer

Sorafenib is an oral multikinase inhibitor approved for the treatment of differentiated thyroid carcinoma (DTC), renal cell carcinoma, and hepatocellular carcinoma. In the phase III DECISION trial in patients with DTC, sorafenib exposure and the incidence of some adverse events (AEs) were higher tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Grevel, Joachim, Jentsch, Garrit, Austin, Rupert, Prins, Nicolaas H., Lettieri, John, Mitchell, David, Huang, Funan, Brose, Marcia S., Schlumberger, Martin, Meinhardt, Gerold, Peña, Carol E. A., Ploeger, Bart A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742948/
https://www.ncbi.nlm.nih.gov/pubmed/30920122
http://dx.doi.org/10.1111/cts.12634

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742948/
https://www.ncbi.nlm.nih.gov/pubmed/30920122
http://dx.doi.org/10.1111/cts.12634

Ejemplares similares